{"entity":{"id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Osimertinib, Pemetrexed, Carboplatin in mesothelioma, run by Vivace Therapeutics, Inc, now recruiting.","summary":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04665206 by Vivace Therapeutics, Inc, with 434 participants planned, started 2021-03-24 and due to reach its primary completion in 2029-11-02. Interventions recorded: VT3989, Nivolumab & Ipilimumab, Osimertinib, Pemetrexed/Carboplatin. Conditions listed: Solid Tumor, Adult, Mesothelioma, NSCLC. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04665206","url":"https://clinicaltrials.gov/study/NCT04665206"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib","pemetrexed","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04665206","phase":"1/2","setting":"Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Vivace Therapeutics, Inc","enrolled":434,"outcomes":[]},"route":"/trials/nct04665206/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}]}}